Dystrophin deficiency exacerbates skeletal muscle pathology in dysferlin-null mice
© Han et al; licensee BioMed Central Ltd. 2011
Received: 25 October 2011
Accepted: 1 December 2011
Published: 1 December 2011
Skip to main content
© Han et al; licensee BioMed Central Ltd. 2011
Received: 25 October 2011
Accepted: 1 December 2011
Published: 1 December 2011
Mutations in the genes coding for either dystrophin or dysferlin cause distinct forms of muscular dystrophy. Dystrophin links the cytoskeleton to the sarcolemma through direct interaction with β-dystroglycan. This link extends to the extracellular matrix by β-dystroglycan's interaction with α-dystroglycan, which binds extracellular matrix proteins, including laminin α2, agrin and perlecan, that possess laminin globular domains. The absence of dystrophin disrupts this link, leading to compromised muscle sarcolemmal integrity. Dysferlin, on the other hand, plays an important role in the Ca2+-dependent membrane repair of damaged sarcolemma in skeletal muscle. Because dysferlin and dystrophin play different roles in maintaining muscle cell integrity, we hypothesized that disrupting sarcolemmal integrity with dystrophin deficiency would exacerbate the pathology in dysferlin-null mice and allow further characterization of the role of dysferlin in skeletal muscle.
To test our hypothesis, we generated dystrophin/dysferlin double-knockout (DKO) mice by breeding mdx mice with dysferlin-null mice and analyzed the effects of a combined deficiency of dysferlin and dystrophin on muscle pathology and sarcolemmal integrity.
The DKO mice exhibited more severe muscle pathology than either mdx mice or dysferlin-null mice, and, importantly, the onset of the muscle pathology occurred much earlier than it did in dysferlin-deficient mice. The DKO mice showed muscle pathology of various skeletal muscles, including the mandible muscles, as well as a greater number of regenerating muscle fibers, higher serum creatine kinase levels and elevated Evans blue dye uptake into skeletal muscles. Lengthening contractions caused similar force deficits, regardless of dysferlin expression. However, the rate of force recovery within 45 minutes following lengthening contractions was hampered in DKO muscles compared to mdx muscles or dysferlin-null muscles, suggesting that dysferlin is required for the initial recovery from lengthening contraction-induced muscle injury of the dystrophin-glycoprotein complex-compromised muscles.
The results of our study suggest that dysferlin-mediated membrane repair helps to limit the dystrophic changes in dystrophin-deficient skeletal muscle. Dystrophin deficiency unmasks the function of dysferlin in membrane repair during lengthening contractions. Dystrophin/dysferlin-deficient mice provide a very useful model with which to evaluate the effectiveness of therapies designed to treat dysferlin deficiency.
Duchenne muscular dystrophy (DMD) is an X-linked recessive disease affecting approximately 1 in 3, 500 males and is caused by defects in the dystrophin gene . Dystrophin is an integral component of the dystrophin-glycoprotein complex (DGC) and is localized to the inner surface of the plasma membrane . Dystrophin plays an important role in linking the cytoskeleton to the sarcolemma through the direct interactions of its N-terminus with F-actin and its C-terminus with β-dystroglycan . This link is extended to the extracellular matrix (ECM) by α-dystroglycan, which binds to laminin α2, agrin and perlecan with high affinity. The dystrophin-mediated continuous link between the cytoskeleton and the ECM is reported to play an important role in stabilizing the sarcolemmal structure, transmitting force laterally and preventing the expansion of muscle membrane damage during lengthening contraction (LC) [3–8]. In DMD patients and mdx mice, which also have a mutation in the dystrophin gene, loss of dystrophin disrupts the link between the cytoskeleton and the ECM, leading to the loss of sarcolemmal integrity. This loss of sarcolemmal integrity eventually results in muscle degeneration, necrosis and fibrosis. As a consequence, DMD patients are confined to a wheelchair in their early teens and die in their early 20s as a result of cardiopulmonary failure .
The plasma membrane provides a physical barrier between the extracellular space and the intracellular environment, and maintenance of this barrier is crucial for the survival of any cell. We previously showed that skeletal muscle possesses the ability to repair membrane wounding in a Ca2+-dependent manner and that dysferlin plays a critical role in this process [10, 11]. Mutations in dysferlin cause limb-girdle muscular dystrophy type 2B [12, 13], Miyoshi myopathy  and a distal anterior compartment myopathy .
Dystrophin deficiency renders the muscle susceptible to contraction-induced sarcolemmal injuries [4–8], whereas dysferlin deficiency results in compromised membrane repair [10, 15–19]. Taking into consideration these two different roles in maintaining sarcolemmal integrity, we hypothesized that skeletal muscle membrane stability mediated by the DGC and dysferlin-mediated membrane repair are both essential for the maintenance of muscle membrane integrity and function. On the basis of this hypothesis, we predicted that a combined deficiency in both dysferlin and dystrophin would lead to more severe muscle pathology due both to an increased susceptibility to muscle membrane injuries in the absence of dystrophin and to defective membrane repair in the absence of dysferlin. To test this hypothesis, we generated mice that lack both dysferlin and dystrophin. The dystrophin/dysferlin double-knockout (DKO) mice developed more severe muscle pathology than either mdx mice or dysferlin-null mice, which is reflected by the higher number of regenerated muscle fibers, increased serum creatine kinase (CK) levels and more Evans blue dye (EBD) uptake in their muscles. These data show that dysferlin-mediated membrane repair limits the severity of dystrophic changes in mdx skeletal muscle.
The DKO mice were generated by breeding female mdx/C57BL/10ScSn (mdx) mice with male dysferlin-null mice  through two generations (Additional file 1, Figure S1). F2 pups were genotyped using recently improved methods for genotyping the dysferlin allele  and the mdx allele  to identify the double-mutant mice. The genetic background of DKO mice is a mixture of C57/BL6, 129/SVJ and C57BL/10ScSn. The wild-type (WT) littermates with the same genetic background were used as controls. Mice were maintained at The University of Iowa Animal Care Unit and treated in accordance with animal use guidelines. All animal studies were authorized by the Animal Care, Use, and Review Committee of The University of Iowa.
Using a Microvette CB 300 (Sarstedt AG & Co, Newton, NC), we collected blood required for quantitative, kinetic determination of serum CK activity by mouse tail vein bleeds from nonanesthetized, restrained mice. Red blood cells were pelleted by centrifugation at 10, 000 rpm for 4 minutes, and serum was separated, collected and analyzed immediately without freezing. Serum CK assays were performed with an enzyme-coupled assay reagent kit (Stanbio Laboratory, Boerne, TX, USA) according to the manufacturer's instructions. Absorbance at 340 nm was measured every 30 seconds for 2 minutes at 37°C so that changes in enzyme activity could be calculated.
Muscles (masseter, quadriceps, hamstrings, gluteus, gastrocnemius, tibialis anterior, iliopsoas and diaphragm) were dissected and frozen in isopentane cooled to -165°C in liquid nitrogen. Seven-micron cryosections were cut and fixed in 10% neutral buffer formalin for five minutes. After fixation, the slides were washed for five minutes under running water followed by H & E staining (Surgipath Medical Industries, Inc/Leica Microsystems, Richmond, IL, USA). H & E-stained sections were analyzed by light microscopy (Leica Microsystems Inc, Buffalo Grove, IL, USA; Carl Zeiss Microscopy, LLC, Thornwood, NY, USA). Immunofluorescence analyses were also performed on 7-μm cryosections. Sections were processed for immunofluorescence microscopy and analyzed with an epifluorescence microscope (Leica Microsystems Inc, and Carl Zeiss Microscopy, LLC). Mouse anti-dysferlin (Hamlet-1, Novocastra, Newcastle, UK) mAb and rabbit pAb against β-dystroglycan , sarcospan , dystrophin (Abcam, Cambridge, MA, USA) and laminin α2 chain (AXXORA LLC, San Diego, CA, USA) were used for immunofluorescence analysis. The central nucleated and total muscle fibers were counted on muscle sections costained with anti-laminin α2 antibody and 4', 6-diamidino-2-phenylindole (Sigma-Aldrich, St Louis, MO, USA) using Image-Pro Plus version 6 software (Media Cybernetics, Inc, Bethesda, MD, USA).
Proteins were extracted from 20 to 35 cryosections (30 μm thick) of quadriceps tissue from each mouse using 250 μl of PBS plus 1% Triton X-100, 0.5% SDS and protease inhibitors. The protein samples in the supernatant were mixed with 80 μl of 5× Laemmli sample buffer, and 70-μl final samples were resolved by SDS-PAGE on 3% to 15% linear gradient gels and transferred onto polyvinylidene fluoride Immobilon-FL membrane (Millipore, Billerica, MA, USA). The membranes were blocked with fish gelatin in Tris-buffered saline (TBS) and incubated with primary antibodies (mouse anti-dysferlin mAb Hamlet, mouse anti-β-dystroglycan 8D5 mAb, mouse anti-dystrophin mAb and rabbit anti-dihydropyridine receptor (anti-DHPR) α2 pAb ). Blots were washed with TBS + 0.1% Tween 20 and incubated with infrared dye-conjugated secondary antibodies (Pierce Biotechnology/Thermo Fisher Scientific, Inc, Rockford, IL, USA). After washing, blots were captured using the Odyssey Imaging System (LI-COR, Lincoln, NE, USA).
Evans blue dye (Sigma-Aldrich) was dissolved in PBS (10 mg/ml) and sterilized through a 0.2-μm pore size filter. The mice were anesthetized by ketamine injection (0.1 ml/10 g body weight), and 0.05 ml/10 g body weight dye solution was injected intraperitoneally. The animals were killed 24 hours after injection, and their skeletal muscles were isolated and frozen in isopentane cooled to -165°C in liquid nitrogen. Microscopic evaluation of EBD uptake was performed on 7-μm muscle cryosections. Muscle cryosections were fixed in cold acetone at -20°C for 10 minutes, washed with PBS, coverslipped in VECTASHIELD Mounting Medium (Vector Laboratories, Burlingame, CA, USA) and evaluated by fluorescence microscopy.
Contractile properties were measured in vitro on extensor digitorum longus (EDL) muscles from WT, dysferlin-null, mdx and DKO mice (12 to 22 weeks of age) as described previously [3, 25]. The mice were anesthetized with an intraperitoneal injection of 2% avertin (0.0015 ml/g body weight), and thoracotomy was performed. EDL muscles were immersed in an oxygenated bath (95% O2, 5% CO2) that contained Ringer's solution (pH 7.4) at 25°C. For each muscle, one end tendon was tied securely with a 6-0 suture to a dual-mode servomotor (Aurora Scientific, Inc, Aurora, ON, Canada) and the other tendon was clamped to a fixed post. Using twitches with a pulse duration of 0.2 milliseconds, the voltage or current of stimulation was increased to achieve a maximum twitch and then increased slightly. Twitches were then used to adjust the muscle length to the optimum length for force development (Lo). Fiber length (Lf) was determined by multiplying Lo by the ratio of fiber length to muscle length (0.45) [3, 25, 26]. The muscle length was set at Lo, and EDL muscles were stimulated for 300 milliseconds. The stimulation frequency was increased until the force reached a plateau at maximum isometric tetanic force (P0). The susceptibility to LC-induced injury was assessed by subjecting each muscle to eight LCs at a rate of one LC every three minutes [3, 25, 26]. Each LC consisted of maximally activating the muscle at a fixed length for 100 milliseconds, then stretching the muscle at a strain of 30% of Lf at a strain a velocity of 1 Lf/second. Muscle activation ceased upon achieving the 30% strain and was returned to Lo at the same velocity. To assess the force deficit generated by this assay, a measurement of P0 was taken three minutes after the last LC and repeated at 15, 30 and 45 minutes. The total fiber cross-sectional area and specific P0 (kN/m2) were calculated based on measurements of muscle mass, Lf and P0. A generalized linear model with repeated-measures analysis of variance (ANOVA) using SPSS software (SPSS, Inc, Chicago, IL, USA) was used to determine whether time after LC, dysferlin and dystrophin were significant factors.
Data were calculated according to analysis of variance (ANOVA) and are expressed as means ± SEM. Where appropriate, the significance of differences between multiple mouse models was assessed using one-way ANOVA with Student-Newman-Keuls posttests, and the significance of differences between two experimental groups were assessed using an unpaired two-tailed Student's t-test. P < 0.05 was accepted as significant.
Membrane disruptions and muscle damage not only allow EBD uptake but also lead to leakage of cytosolic contents such as CK, which can then be detected in the serum. Measurements of serum CK levels provide an index of the active skeletal muscle necrosis and the presence of membrane disruptions. Our analysis revealed that the DKO mice had serum CK levels twofold higher than those of mdx mice and tenfold higher than those of dysferlin-null mice (Figure 4B). Taken together, these data suggest that the dystrophin and dysferlin double-deficiency results in decreased sarcolemmal integrity.
Skeletal muscle is associated with significant stress and strain during muscle contraction. Previous studies have shown at least two mechanisms that skeletal muscle cells utilize to maintain sarcolemmal integrity: a tightly associated basal lamina mediated by the dystroglycan complex limits the extent of plasma membrane damage  and membrane repair machinery involving multiple proteins that actively restore membrane integrity following limited levels of membrane disruption, such as dysferlin [10, 15, 18]; calpain ; annexins A1, A2 and A5 [18, 30, 31]; and MG53 [32, 33]. A defect in either mechanism is detrimental to the muscle, as manifested by the fact that genetic mutations in either the DGC components (for review, see ) or dysferlin [12–14] cause various muscular dystrophies. In the present work using mouse models, we have further demonstrated that a double-deficiency in both dystrophin and dysferlin results in more severe muscular dystrophy. The results of our work are in agreement with those of Shaw et al. , who showed that mice overexpressing the Coxsackie virus and adenovirus receptor transgene demonstrate decreased expression levels of dystrophin and dysferlin, which may lead to an associated myopathy. Our work provides genetic evidence that dysferlin and the DGC are independent pathways for the maintenance of sarcolemmal integrity in muscle and further highlights the importance of these two pathways in muscle health.
Contraction-induced injury is characterized by two distinct phases: an initial injury and a delayed secondary injury from the inflammatory response. The initial injury consists of mechanical disruption of sarcomeres followed by impaired excitation-contraction coupling and Ca2+ signaling and finally by activation of Ca2+-sensitive degradation pathways . Interestingly, for muscle with an intact DGC, whether membrane damage occurs during the initial injury phase is unclear; but if it exists, it is dysferlin-independent [25, 37, 38]. Several hours to days following the initial injury, infiltration of inflammatory factors damage muscle fibers and release reactive oxygen species (ROS), which aid in clearing disrupted myofibrils but also damage previously undamaged myofibrils. At this stage, ROS potentially cause damage to the sarcolemma, possibly through lipid peroxidation [39, 40]. Investigators in previous studies have demonstrated that dysferlin is important in limiting the extent of secondary injury. For example, three days following a protocol of small strain LCs, muscles of dysferlin-deficient mice displayed increased macrophage infiltration, decreased ability to seal off a membrane-impermeable dye and increased force deficits [38, 41]. These data indicate that defects in membrane repair or alteration in repair result in chemoattraction of immune cells [38, 41].
Previously, we demonstrated that a combined deficiency in dysferlin and dystrophin results in the development of a pronounced early-onset cardiomyopathy resembling that seen in DMD patients, in contrast to a mild, slowly progressing cardiac manifestation in mdx mice . Thus the DKO mouse model is well-suited to the study of the molecular mechanisms of and therapy for cardiomyopathy in DMD. Our present study reveals for the first time that dystrophin deficiency unmasks a role for dysferlin in repairing membrane damage during the initial injury elicited by LCs. Compared to WT skeletal muscle, mdx muscle had a much greater force deficit measured three minutes after LC (78% in mdx vs 31% in WT). However, by 45 minutes, the force in mdx muscles recovered from 22% to over 60% of the preinjury level, whereas the WT and dysferlin-null muscles gained only 10% (from 69% to 79%) and 6% (from 65% to 71%), respectively. These data suggest that, unlike WT and dysferlin-null muscle, in which LCs induce little membrane damage, mdx muscle undergoes more severe membrane damage, which requires an active membrane repair process to restore membrane integrity. DKO muscles are also repair-competent, as the force also recovered from 16% at 3 minutes to 52% at 45 minutes. However, by comparing the recovery rate constants of mdx muscles and DKO muscles, we found that the recovery rate of the DKO muscles was less than half the rate of mdx muscles. Therefore, our data derived from using a LC assay reveal that dystrophin deficiency sufficiently unmasks the membrane repair role of dysferlin. The DKO mouse would be a very useful model with which to determine the efficacy of a therapeutic treatment designed for dysferlinopathy.
Taken together, our results show that both DGC-mediated membrane stability and dysferlin-mediated membrane repair contribute to the function and maintenance of skeletal muscle. The studies presented here suggest that the DKO mouse model may be a valuable tool in the development of therapies designed to treat dysferlinopathies.
Duchenne muscular dystrophy
Evans blue dye
extensor digitorum longus
hematoxylin and eosin
reactive oxygen species.
We thank Keith Garringer, Samantha K Watkins, Sally Prouty and David P Venzke for technical support and Drs Yvonne Kobayashi, Li Xu and Piming Zhao for critical reading and discussion. This work was supported in part by American Heart Association Scientist Development grant 10SDG4140138 (to RH), Muscular Dystrophy Association Research Grant MDA171667 (to RH), Paul D Wellstone Muscular Dystrophy Cooperative Research Center grant 1U54NS053672 (to KPC), Muscular Dystrophy Association grant MDA3936 (to KPC), Muscular Dystrophy Association Development grants MDA200826 (to JRL) and MDA67814 (to EPR) and US Department of Defense grant W81XWH-05-1-0079. The authors declare no conflicts of interest. KPC is an investigator at the Howard Hughes Medical Institute.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.